Pharmaceutical company Eli Lilly has agreed to buy Calytrix Bio for up to $1.5 billion in cash, Reuters reports. The deal will allow the pharmaceutical giant to expand the development of drugs to treat rare blood diseases. The agreement stipulates an advance and graduated payments based on the results of clinical and regulatory trials.